Circulating Tissue Factor Pathway Inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia
Teresa M MacDonald, Stephen Tong, Jenny Myers, Ping Cannon, Nguyen Tuong-Vi, Emerson Keenan, Elizabeth Murray, Alesia Harper, Natasha Pritchard, Natalie J Hannan, Kirsten M Dane, Anna L Middleton, Valerie P Kyritsis, Susan P Walker, Tu'uhevaha J Kaitu'u-Lino
PLACENTA | W B SAUNDERS CO LTD | Published : 2021
INTRODUCTION: Tissue Factor Pathway Inhibitor (TFPI) is a part of the extrinsic coagulation pathway, and highly expressed in the placenta. We aimed to assess its potential as a preeclampsia biomarker. METHODS: Maternal plasma was prospectively collected at 36 weeks' gestation. Circulating TFPI was measured in a nested case-control group (39 women who developed preeclampsia, 98 controls), before being measured in a larger independent cohort along with Placental Growth Factor (PlGF; 41 who developed preeclampsia, 954 controls). Circulating TFPI was then measured in women with underlying vascular disease, and also assessed in the plasma and placentas from women with preterm preeclampsia (delive..View full abstract
Related Projects (5)
Awarded by National Health and Medical Research Council
Funding for this work was provided by the National Health and Medical Research Council (#1065854, #1183854, #116071), and the Norman Beischer Medical Research Foundation; Australian Government Research Training Program Scholarship, and RANZCOG Taylor Hammond Scholarship to TM; National Health and Medical Research Council Fellowships to TKL (#1159261), NJH (#1146128) and ST (#1136418). The funders played no role in study design or analysis.